Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 42

1.

Novel plasma peptide markers involved in the pathology of CKD identified using mass spectrometric approach.

Gajjala PR, Bruck H, Noels H, Heinze G, Ceccarelli F, Kribben A, Saez-Rodriguez J, Marx N, Zidek W, Jankowski J, Jankowski V.

J Mol Med (Berl). 2019 Oct;97(10):1451-1463. doi: 10.1007/s00109-019-01823-8. Epub 2019 Aug 5.

2.

A Bifunctional Adsorber Particle for the Removal of Hydrophobic Uremic Toxins from Whole Blood of Renal Failure Patients.

Sternkopf M, Thoröe-Boveleth S, Beck T, Oleschko K, Erlenkötter A, Tschulena U, Steppan S, Speer T, Goettsch C, Jankowski V, Jankowski J, Noels H; European Uremic Toxin Work Group-EUTox.

Toxins (Basel). 2019 Jul 3;11(7). pii: E389. doi: 10.3390/toxins11070389.

3.

Elevated expression of the metalloproteinase ADAM8 associates with vascular diseases in mice and humans.

Schick D, Babendreyer A, Wozniak J, Awan T, Noels H, Liehn E, Bartsch JW, Vlacil AK, Grote K, Zayat R, Goetzenich A, Ludwig A, Dreymueller D.

Atherosclerosis. 2019 Jul;286:163-171. doi: 10.1016/j.atherosclerosis.2019.03.008. Epub 2019 Mar 17.

PMID:
30910225
4.

Hematopoietic ChemR23 (Chemerin Receptor 23) Fuels Atherosclerosis by Sustaining an M1 Macrophage-Phenotype and Guidance of Plasmacytoid Dendritic Cells to Murine Lesions-Brief Report.

van der Vorst EPC, Mandl M, Müller M, Neideck C, Jansen Y, Hristov M, Gencer S, Peters LJF, Meiler S, Feld M, Geiselhöringer AL, de Jong RJ, Ohnmacht C, Noels H, Soehnlein O, Drechsler M, Weber C, Döring Y.

Arterioscler Thromb Vasc Biol. 2019 Apr;39(4):685-693. doi: 10.1161/ATVBAHA.119.312386.

PMID:
30786742
5.

Chemokines as Therapeutic Targets in Cardiovascular Disease.

Noels H, Weber C, Koenen RR.

Arterioscler Thromb Vasc Biol. 2019 Apr;39(4):583-592. doi: 10.1161/ATVBAHA.118.312037.

PMID:
30760014
6.

Golgin A4 in CSF and granulovacuolar degenerations of patients with Alzheimer disease.

Kork F, Jankowski J, Goswami A, Weis J, Brook G, Yamoah A, Anink J, Aronica E, Fritz S, Huck C, Schipke C, Peters O, Tepel M, Noels H, Jankowski V.

Neurology. 2018 Nov 6;91(19):e1799-e1808. doi: 10.1212/WNL.0000000000006457. Epub 2018 Oct 10.

PMID:
30305446
7.

Reduced post-operative DPP4 activity associated with worse patient outcome after cardiac surgery.

Noels H, Theelen W, Sternkopf M, Jankowski V, Moellmann J, Kraemer S, Lehrke M, Marx N, Martin L, Marx G, Jankowski J, Goetzenich A, Stoppe C.

Sci Rep. 2018 Aug 7;8(1):11820. doi: 10.1038/s41598-018-30235-w.

8.

Systematic RNA-interference in primary human monocyte-derived macrophages: A high-throughput platform to study foam cell formation.

Domschke G, Linden F, Pawig L, Hafner A, Akhavanpoor M, Reymann J, Doesch AO, Erbel C, Weber C, Katus HA, Noels H, Erfle H, Gleissner CA, Runz H.

Sci Rep. 2018 Jul 12;8(1):10516. doi: 10.1038/s41598-018-28790-3.

9.

Prolyl carboxypeptidase activity in the circulation and its correlation with body weight and adipose tissue in lean and obese subjects.

Kehoe K, Noels H, Theelen W, De Hert E, Xu S, Verrijken A, Arnould T, Fransen E, Hermans N, Lambeir AM, Venge P, Van Gaal L, De Meester I.

PLoS One. 2018 May 17;13(5):e0197603. doi: 10.1371/journal.pone.0197603. eCollection 2018.

10.

Interferon-induced protein 35 inhibits endothelial cell proliferation, migration and re-endothelialization of injured arteries by inhibiting the nuclear factor-kappa B pathway.

Schulte C, Noels H.

Acta Physiol (Oxf). 2018 Jul;223(3):e13091. doi: 10.1111/apha.13091. Epub 2018 May 22. No abstract available.

PMID:
29749090
11.

Mechanisms of cardiovascular complications in chronic kidney disease: research focus of the Transregional Research Consortium SFB TRR219 of the University Hospital Aachen (RWTH) and the Saarland University.

Marx N, Noels H, Jankowski J, Floege J, Fliser D, Böhm M.

Clin Res Cardiol. 2018 Aug;107(Suppl 2):120-126. doi: 10.1007/s00392-018-1260-0. Epub 2018 May 4. Review.

PMID:
29728829
12.

The new SFB/TRR219 Research Centre.

Noels H, Boor P, Goettsch C, Hohl M, Jahnen-Dechent W, Jankowski V, Kindermann I, Kramann R, Lehrke M, Linz D, Maack C, Niemeyer B, Roma LP, Schuett K, Speer T, Wagenpfeil S, Werner C, Zewinger S, Böhm M, Marx N, Floege J, Fliser D, Jankowski J.

Eur Heart J. 2018 Mar 21;39(12):975-977. doi: 10.1093/eurheartj/ehy083. No abstract available.

PMID:
29579229
13.

Mif-deficiency favors an atheroprotective autoantibody phenotype in atherosclerosis.

Schmitz C, Noels H, El Bounkari O, Straussfeld E, Megens RTA, Sternkopf M, Alampour-Rajabi S, Krammer C, Tilstam PV, Gerdes N, Bürger C, Kapurniotu A, Bucala R, Jankowski J, Weber C, Bernhagen J.

FASEB J. 2018 Aug;32(8):4428-4443. doi: 10.1096/fj.201800058R. Epub 2018 Mar 15.

14.

Proteomic-Biostatistic Integrated Approach for Finding the Underlying Molecular Determinants of Hypertension in Human Plasma.

Gajjala PR, Jankowski V, Heinze G, Bilo G, Zanchetti A, Noels H, Liehn E, Perco P, Schulz A, Delles C, Kork F, Biessen E, Narkiewicz K, Kawecka-Jaszcz K, Floege J, Soranna D, Zidek W, Jankowski J.

Hypertension. 2017 Aug;70(2):412-419. doi: 10.1161/HYPERTENSIONAHA.116.08906. Epub 2017 Jun 26.

PMID:
28652472
15.

Vascular CXCR4 Limits Atherosclerosis by Maintaining Arterial Integrity: Evidence From Mouse and Human Studies.

Döring Y, Noels H, van der Vorst EPC, Neideck C, Egea V, Drechsler M, Mandl M, Pawig L, Jansen Y, Schröder K, Bidzhekov K, Megens RTA, Theelen W, Klinkhammer BM, Boor P, Schurgers L, van Gorp R, Ries C, Kusters PJH, van der Wal A, Hackeng TM, Gäbel G, Brandes RP, Soehnlein O, Lutgens E, Vestweber D, Teupser D, Holdt LM, Rader DJ, Saleheen D, Weber C.

Circulation. 2017 Jul 25;136(4):388-403. doi: 10.1161/CIRCULATIONAHA.117.027646. Epub 2017 Apr 27.

16.

Inhibition of atherogenesis by the COP9 signalosome subunit 5 in vivo.

Asare Y, Ommer M, Azombo FA, Alampour-Rajabi S, Sternkopf M, Sanati M, Gijbels MJ, Schmitz C, Sinitski D, Tilstam PV, Lue H, Gessner A, Lange D, Schmid JA, Weber C, Dichgans M, Jankowski J, Pardi R, de Winther MP, Noels H, Bernhagen J.

Proc Natl Acad Sci U S A. 2017 Mar 28;114(13):E2766-E2775. doi: 10.1073/pnas.1618411114. Epub 2017 Mar 14.

17.

β7-Integrin and MAdCAM-1 play opposing roles during the development of non-alcoholic steatohepatitis.

Drescher HK, Schippers A, Clahsen T, Sahin H, Noels H, Hornef M, Wagner N, Trautwein C, Streetz KL, Kroy DC.

J Hepatol. 2017 Jun;66(6):1251-1264. doi: 10.1016/j.jhep.2017.02.001. Epub 2017 Feb 10.

PMID:
28192190
18.

Editorial: The CXCR4 Ligand/Receptor Family and the DPP4 Protease in High-Risk Cardiovascular Patients.

Noels H, Bernhagen J.

Front Immunol. 2016 Feb 19;7:58. doi: 10.3389/fimmu.2016.00058. eCollection 2016. No abstract available.

19.

Diversity and Inter-Connections in the CXCR4 Chemokine Receptor/Ligand Family: Molecular Perspectives.

Pawig L, Klasen C, Weber C, Bernhagen J, Noels H.

Front Immunol. 2015 Aug 21;6:429. doi: 10.3389/fimmu.2015.00429. eCollection 2015. Review.

20.

Evaluation of the BDCA2-DTR Transgenic Mouse Model in Chronic and Acute Inflammation.

Mandl M, Drechsler M, Jansen Y, Neideck C, Noels H, Faussner A, Soehnlein O, Weber C, Döring Y.

PLoS One. 2015 Aug 7;10(8):e0134176. doi: 10.1371/journal.pone.0134176. eCollection 2015.

21.

Platelet CD40L Modulates Thrombus Growth Via Phosphatidylinositol 3-Kinase β, and Not Via CD40 and IκB Kinase α.

Kuijpers MJ, Mattheij NJ, Cipolla L, van Geffen JP, Lawrence T, Donners MM, Boon L, Lievens D, Torti M, Noels H, Gerdes N, Cosemans JM, Lutgens E, Heemskerk JW.

Arterioscler Thromb Vasc Biol. 2015 Jun;35(6):1374-81. doi: 10.1161/ATVBAHA.114.305127. Epub 2015 Apr 23.

PMID:
25908768
22.

Potential cell-specific functions of CXCR4 in atherosclerosis.

Weber C, Döring Y, Noels H.

Hamostaseologie. 2016 May 10;36(2):97-102. doi: 10.5482/HAMO-14-10-0054. Epub 2015 Jan 14. Review.

PMID:
25586789
23.

The CXCL12/CXCR4 chemokine ligand/receptor axis in cardiovascular disease.

Döring Y, Pawig L, Weber C, Noels H.

Front Physiol. 2014 Jun 11;5:212. doi: 10.3389/fphys.2014.00212. eCollection 2014. Review.

24.

Deficiency of endothelial CXCR4 reduces reendothelialization and enhances neointimal hyperplasia after vascular injury in atherosclerosis-prone mice.

Noels H, Zhou B, Tilstam PV, Theelen W, Li X, Pawig L, Schmitz C, Akhtar S, Simsekyilmaz S, Shagdarsuren E, Schober A, Adams RH, Bernhagen J, Liehn EA, Döring Y, Weber C.

Arterioscler Thromb Vasc Biol. 2014 Jun;34(6):1209-20. doi: 10.1161/ATVBAHA.113.302878. Epub 2014 Apr 10.

PMID:
24723559
25.

MicroRNA-126-5p promotes endothelial proliferation and limits atherosclerosis by suppressing Dlk1.

Schober A, Nazari-Jahantigh M, Wei Y, Bidzhekov K, Gremse F, Grommes J, Megens RT, Heyll K, Noels H, Hristov M, Wang S, Kiessling F, Olson EN, Weber C.

Nat Med. 2014 Apr;20(4):368-76. doi: 10.1038/nm.3487. Epub 2014 Mar 2.

26.

Bone marrow-specific knock-in of a non-activatable Ikkα kinase mutant influences haematopoiesis but not atherosclerosis in Apoe-deficient mice.

Tilstam PV, Gijbels MJ, Habbeddine M, Cudejko C, Asare Y, Theelen W, Zhou B, Döring Y, Drechsler M, Pawig L, Simsekyilmaz S, Koenen RR, de Winther MP, Lawrence T, Bernhagen J, Zernecke A, Weber C, Noels H.

PLoS One. 2014 Feb 3;9(2):e87452. doi: 10.1371/journal.pone.0087452. eCollection 2014.

27.

Deficiency of the sialyltransferase St3Gal4 reduces Ccl5-mediated myeloid cell recruitment and arrest: short communication.

Döring Y, Noels H, Mandl M, Kramp B, Neideck C, Lievens D, Drechsler M, Megens RT, Tilstam PV, Langer M, Hartwig H, Theelen W, Marth JD, Sperandio M, Soehnlein O, Weber C.

Circ Res. 2014 Mar 14;114(6):976-81. doi: 10.1161/CIRCRESAHA.114.302426. Epub 2014 Jan 14.

28.

Arrest Functions of the MIF Ligand/Receptor Axes in Atherogenesis.

Tillmann S, Bernhagen J, Noels H.

Front Immunol. 2013 May 16;4:115. doi: 10.3389/fimmu.2013.00115. eCollection 2013.

29.

Endothelial CSN5 impairs NF-κB activation and monocyte adhesion to endothelial cells and is highly expressed in human atherosclerotic lesions.

Asare Y, Shagdarsuren E, Schmid JA, Tilstam PV, Grommes J, El Bounkari O, Schütz AK, Weber C, de Winther MP, Noels H, Bernhagen J.

Thromb Haemost. 2013 Jul;110(1):141-52. doi: 10.1160/TH13-02-0155. Epub 2013 May 2.

PMID:
23636414
30.

MicroRNA-155 promotes atherosclerosis by repressing Bcl6 in macrophages.

Nazari-Jahantigh M, Wei Y, Noels H, Akhtar S, Zhou Z, Koenen RR, Heyll K, Gremse F, Kiessling F, Grommes J, Weber C, Schober A.

J Clin Invest. 2012 Nov;122(11):4190-202. doi: 10.1172/JCI61716. Epub 2012 Oct 8.

31.

The use of high-throughput technologies to investigate vascular inflammation and atherosclerosis.

Döring Y, Noels H, Weber C.

Arterioscler Thromb Vasc Biol. 2012 Feb;32(2):182-95. doi: 10.1161/ATVBAHA.111.232686. Review.

PMID:
22258901
32.

Atherosclerosis: current pathogenesis and therapeutic options.

Weber C, Noels H.

Nat Med. 2011 Nov 7;17(11):1410-22. doi: 10.1038/nm.2538. Review.

PMID:
22064431
33.

Catching up with important players in atherosclerosis: type I interferons and neutrophils.

Noels H, Weber C.

Curr Opin Lipidol. 2011 Apr;22(2):144-5. doi: 10.1097/MOL.0b013e328344780b. No abstract available.

PMID:
21415605
34.

Cleavage of NIK by the API2-MALT1 fusion oncoprotein leads to noncanonical NF-kappaB activation.

Rosebeck S, Madden L, Jin X, Gu S, Apel IJ, Appert A, Hamoudi RA, Noels H, Sagaert X, Van Loo P, Baens M, Du MQ, Lucas PC, McAllister-Lucas LM.

Science. 2011 Jan 28;331(6016):468-72. doi: 10.1126/science.1198946. Erratum in: Science. 2011 Apr 22;332(6028):421.

36.

Delivery of microRNA-126 by apoptotic bodies induces CXCL12-dependent vascular protection.

Zernecke A, Bidzhekov K, Noels H, Shagdarsuren E, Gan L, Denecke B, Hristov M, Köppel T, Jahantigh MN, Lutgens E, Wang S, Olson EN, Schober A, Weber C.

Sci Signal. 2009 Dec 8;2(100):ra81. doi: 10.1126/scisignal.2000610.

PMID:
19996457
37.

Macrophage migration inhibitory factor: a noncanonical chemokine important in atherosclerosis.

Noels H, Bernhagen J, Weber C.

Trends Cardiovasc Med. 2009 Apr;19(3):76-86. doi: 10.1016/j.tcm.2009.05.002. Review.

PMID:
19679264
38.

Auto-ubiquitination-induced degradation of MALT1-API2 prevents BCL10 destabilization in t(11;18)(q21;q21)-positive MALT lymphoma.

Noels H, Somers R, Liu H, Ye H, Du MQ, De Wolf-Peeters C, Marynen P, Baens M.

PLoS One. 2009;4(3):e4822. doi: 10.1371/journal.pone.0004822. Epub 2009 Mar 12.

39.

A Novel TRAF6 binding site in MALT1 defines distinct mechanisms of NF-kappaB activation by API2middle dotMALT1 fusions.

Noels H, van Loo G, Hagens S, Broeckx V, Beyaert R, Marynen P, Baens M.

J Biol Chem. 2007 Apr 6;282(14):10180-9. Epub 2007 Feb 7.

40.

The pathogenesis of MALT lymphomas: where do we stand?

Sagaert X, De Wolf-Peeters C, Noels H, Baens M.

Leukemia. 2007 Mar;21(3):389-96. Epub 2007 Jan 18. Review.

PMID:
17230229
41.

The dark side of EGFP: defective polyubiquitination.

Baens M, Noels H, Broeckx V, Hagens S, Fevery S, Billiau AD, Vankelecom H, Marynen P.

PLoS One. 2006 Dec 20;1:e54.

42.

Selective expansion of marginal zone B cells in Emicro-API2-MALT1 mice is linked to enhanced IkappaB kinase gamma polyubiquitination.

Baens M, Fevery S, Sagaert X, Noels H, Hagens S, Broeckx V, Billiau AD, De Wolf-Peeters C, Marynen P.

Cancer Res. 2006 May 15;66(10):5270-7.

Supplemental Content

Support Center